Literature DB >> 23770850

Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.

X-W Yang1, P Wang1, J-Q Liu1, H Zhang1, W-D Xi1, X-H Jia1, K-K Wang1.   

Abstract

Recognition and elimination of malignant cells by cytotoxic T lymphocytes depends on antigenic peptides generated by proteasomes. It has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. We report here the regulatory mechanism of the repression of PU.1-dependent activation of PSMBs by PML/RARα in the pathogenesis of acute promyelocytic leukemia (APL) and the unidentified function of all-trans retinoic acid (ATRA) as an immunomodulator in the treatment of APL. Chromatin immunoprecipitation and luciferase reporter assays showed that PU.1 directly bound to and coordinately transactivated the promoters of PSMBs, indicating that PSMBs were transcriptional targets of PU.1 and PU.1 regulated their basal expression. Analysis of expression profiling data from a large population of acute myeloid leukemia (AML) patients revealed that the expression levels of PSMBs were significantly lower in APL patients than in non-APL AML patients. Further evidence demonstrated that the decrease in their expression was achieved through PML/RARα-mediated repression of both PU.1-dependent transactivation and PU.1 expression. Moreover, ATRA but not arsenic trioxide induced the expression of PSMBs in APL cells, indicating that ATRA treatment might activate the antigen-processing/presentation machinery. Finally, the above observations were confirmed in primary APL samples. Collectively, our data demonstrate that PML/RARα suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770850     DOI: 10.1038/onc.2013.224

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.

Authors:  Frank G Rücker; Anna Dolnik; Tamara J Blätte; Veronica Teleanu; Aurélie Ernst; Felicitas Thol; Michael Heuser; Arnold Ganser; Hartmut Döhner; Konstanze Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

2.  A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.

Authors:  Yun Tan; Xiaoling Wang; Huan Song; Yi Zhang; Rongsheng Zhang; Shufen Li; Wen Jin; Saijuan Chen; Hai Fang; Zhu Chen; Kankan Wang
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

3.  Proteasome functioning in breast cancer: connection with clinical-pathological factors.

Authors:  Elena E Shashova; Yulia V Lyupina; Svetlana A Glushchenko; Elena M Slonimskaya; Olga V Savenkova; Alexey M Kulikov; Nikolay G Gornostaev; Irina V Kondakova; Natalia P Sharova
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

4.  Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.

Authors:  Heriberto Bruzzoni-Giovanelli; Juan R González; François Sigaux; Bruno O Villoutreix; Jean Michel Cayuela; Joëlle Guilhot; Claude Preudhomme; François Guilhot; Jean-Luc Poyet; Philippe Rousselot
Journal:  Oncotarget       Date:  2015-11-03

5.  Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

Authors:  Robert A van den Berg; Margherita Coccia; W Ripley Ballou; Kent E Kester; Christian F Ockenhouse; Johan Vekemans; Erik Jongert; Arnaud M Didierlaurent; Robbert G van der Most
Journal:  Front Immunol       Date:  2017-05-23       Impact factor: 7.561

6.  The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia.

Authors:  Emiliano Fabiani; Giulia Falconi; Nélida Inés Noguera; Ernestina Saulle; Laura Cicconi; Mariadomenica Divona; Cristina Banella; Alessandra Picardi; Anna Maria Cerio; Letizia Boe; Massimo Sanchez; Elvira Pelosi; Ugo Testa; Francesco Lo-Coco; Maria Teresa Voso
Journal:  Oncotarget       Date:  2017-09-20

7.  PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.

Authors:  Xianwen Yang; Yun Tan; Ping Wang; Hui Zhang; Ming Zhao; Xujie Zhao; Kankan Wang
Journal:  J Cell Mol Med       Date:  2018-10-15       Impact factor: 5.310

8.  PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation.

Authors:  Shuyong Wei; Ming Zhao; Xiaoling Wang; Yizhen Li; Kankan Wang
Journal:  J Hematol Oncol       Date:  2016-05-04       Impact factor: 17.388

Review 9.  Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation.

Authors:  Irina V Kondakova; Elena E Shashova; Evgenia A Sidenko; Tatiana M Astakhova; Liudmila A Zakharova; Natalia P Sharova
Journal:  Biomolecules       Date:  2020-03-26

10.  Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia.

Authors:  Ping Wang; Zhonghui Tang; Byoungkoo Lee; Jacqueline Jufen Zhu; Liuyang Cai; Przemyslaw Szalaj; Simon Zhongyuan Tian; Meizhen Zheng; Dariusz Plewczynski; Xiaoan Ruan; Edison T Liu; Chia-Lin Wei; Yijun Ruan
Journal:  Genome Biol       Date:  2020-05-11       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.